Filing identity and period
Important source mismatch: The request identifies Lisata Therapeutics, Inc. and 2021 Q2, but the provided filing is Caladrius Biosciences, Inc.’s Form 10-Q for the quarter ended June 30, 2022, filed August 4, 2022. This summary reflects the filing provided.
Business context
Caladrius was a clinical-stage biopharmaceutical company developing CD34+ cell therapies. Its candidates included XOWNA for coronary microvascular dysfunction, HONEDRA for critical limb ischemia and Buerger’s disease, and CLBS201 for diabetic kidney disease. The company had no reported revenue and was funding research and corporate activities from existing resources.
Financial highlights
Amounts below are in millions of dollars, except per-share data.
| Metric | Three months ended June 30, 2022 | Six months ended June 30, 2022 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development | $3.239 | $6.517 |
| General and administrative | $3.481 | $6.823 |
| Total operating expenses | $6.720 | $13.340 |
| Net loss | $6.626 | $10.852 |
| Loss per share | $0.11 | $0.18 |
| Operating cash used | Not provided for quarter | $10.704 |
At June 30, cash and cash equivalents were $33.348 million and marketable securities were $39.643 million, totaling approximately $73.0 million. Working capital was approximately $71.6 million. Total liabilities were $3.740 million; the filing reports no borrowings or debt balance. Management said existing cash was expected to fund operations for at least 12 months after issuance of the financial statements, absent an impact from the proposed merger. No revenue-based margins are meaningful.
Changes versus prior comparable periods
- Second-quarter operating expenses fell 6% year over year; R&D declined 25% to $3.239 million, while G&A rose 24% to $3.481 million, primarily due to Cend merger-related fees. Net loss increased to $6.626 million from $5.682 million, partly because the prior-year quarter included a $1.508 million income-tax benefit.
- First-half operating expenses declined 12% year over year. R&D decreased 31%, partly reflecting lower manufacturing start-up and process-development costs for XOWNA and lower HONEDRA costs. G&A rose 17% amid strategic-transaction and merger expenses. First-half net loss improved to $10.852 million from $13.745 million, including a $2.5 million tax benefit from selling New Jersey NOL tax benefits for $2.3 million net proceeds.
- Cash and marketable securities together declined from approximately $95.0 million at December 31, 2021 to $73.0 million at June 30, 2022. The company invested $10 million in Cend; net cash from investing activities also reflected net sales of marketable securities.
Outlook, developments, and risks
- Proposed Cend merger: The April 2022 agreement contemplated roughly 50% ownership for each company’s pre-merger stockholders, subject to adjustments. Closing required stockholder approvals and a minimum Caladrius net-cash threshold, expected to be about $64.9 million assuming a late-third-quarter 2022 closing. The company had purchased $10 million of Cend Series D preferred stock. Termination fees and expense reimbursements could apply in specified circumstances.
- Clinical programs: FREEDOM Trial enrollment for XOWNA was suspended; an interim analysis of at least 20 patients’ six-month follow-up data was expected in Q3 2022, with development next steps anticipated before year-end. HONEDRA enrollment in Japan was suspended amid COVID-19 disruption; the company was consulting PMDA and seeking a Japanese partner. CLBS201 treated all six planned subjects in Q3 2022, with top-line data expected by Q1 2023.
- Liquidity and listing: Management warned that additional capital may be difficult to obtain on acceptable terms. Nasdaq had notified the company that its share price did not meet the $1 minimum bid requirement, with an initial compliance deadline of August 17, 2022; continued noncompliance could lead to delisting. The ATM facility could not be used while the listing deficiency persisted.
- Other risks: COVID-19 had delayed trials and could further disrupt operations and timelines. The filing also highlights merger completion, net-cash requirements, potential dilution, termination costs, clinical and regulatory uncertainty, and the need for financing or partnerships.
Important facts for investors to verify
- Confirm the intended issuer and reporting period: the supplied document is Caladrius Biosciences’ Q2 2022 10-Q, not a Lisata Therapeutics Q2 2021 filing.
- Check subsequent disclosures on whether the Cend merger closed, its final terms, and the company’s closing net cash.
- Review subsequent XOWNA interim-analysis and development decisions, HONEDRA regulatory and partnering progress, and CLBS201 data.
- Verify cash runway against actual operating cash use, transaction costs, and any financing or partnership proceeds.
- Check Nasdaq listing compliance and any reverse stock split or other capital actions.